Gilead secures license for cancer treatment candidate By Investing.com

Published on 28 Mar 2024 on Investing.com

Gilead Sciences, Inc. (NASDAQ:GILD) and Xilio Therapeutics, Inc. (NASDAQ:XLO) have entered into an...

Read the rest of the article

Start tracking your investments with Statfolio

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefo...

Zacks via Yahoo Finance 29 Apr 2024

Gilead Sciences, Inc. GILD reported better-than-expected results in the first quarter, as its los...

Zacks via Yahoo Finance 26 Apr 2024

Total Revenue: Reached $6.7 billion in Q1 2024, a 5% increase year-over-year, exceeding estimates...

GuruFocus.com via Yahoo Finance 25 Apr 2024

Gilead Sciences, Inc. (NASDAQ:GILD) has reported a revenue increase in its first quarter of 2024,...

Investing.com 25 Apr 2024

The first-quarter 2024 reporting cycle of the Medical sector is about to pick up pace this week. ...

Zacks via Yahoo Finance 24 Apr 2024

Gilead Sciences Inc. GILD is set to report first-quarter 2024 results on Apr 25, after market clo...

Zacks via Yahoo Finance 22 Apr 2024

Following an investigation announced in November last year, the FDA said on Thursday that it woul...

Benzinga 19 Apr 2024

The U.S. Food and Drug Administration said on Thursday cancer therapies that use CAR-T technology...

Reuters 18 Apr 2024

Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it mig...

Zacks via Yahoo Finance 16 Apr 2024

Broadening our ability to tackle breast cancer are several biotech developments including from...

KAMR Amarillo 11 Apr 2024